Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um Estudo para Investigar Sonrotoclax (BGB-11417) mais Zanubrutinib (BGB-3111) Comparado com Venetoclax mais Acalabrutinib em Adultos com Leucemia Linfocítica Crónica Anteriormente Não Tratada

24 de setembro de 2026 atualizado por: BeOne Medicines

Um Estudo de Fase 3, Aberto, Randomizado de Sonrotoclax (BGB-11417) mais Zanubrutinib (BGB-3111) Comparado com Venetoclax mais Acalabrutinib em Doentes com Leucemia Linfocítica Crónica Anteriormente Não Tratada

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

500

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Deggendorf, Alemanha, 94469
        • Recrutamento
        • Donauisar Klinikum Deggendorf Klinik Fur Onkologie Und Hamatologie
      • Frankfurt am Main, Alemanha, 60389
        • Recrutamento
        • Centrum Fur Haematologie Und Onkologie Bethanien
      • Münster, Alemanha, 48153
        • Recrutamento
        • Geho Munster
      • Straubing, Alemanha, 94315
        • Recrutamento
        • Klinikum St Elisabeth Straubing Gmbh Mvz Klinikum Straubing Gmbh
    • New South Wales
      • Blacktown, New South Wales, Austrália, NSW 2148
        • Recrutamento
        • Blacktown Cancer and Haematology Centre
      • Concord, New South Wales, Austrália, NSW 2139
        • Recrutamento
        • Concord Repatriation General Hospital
      • St Leonards, New South Wales, Austrália, NSW 2065
        • Recrutamento
        • Genesiscare North Shore
    • Queensland
      • Woolloongabba, Queensland, Austrália, QLD 4102
        • Recrutamento
        • Princess Alexandra Hospital
    • Victoria
      • Clayton, Victoria, Austrália, VIC 3168
        • Recrutamento
        • Monash Health
      • Heidelberg, Victoria, Austrália, VIC 3084
        • Recrutamento
        • Austin Health
      • Malvern, Victoria, Austrália, VIC 3144
        • Recrutamento
        • Cabrini Hospital Malvern
      • Melbourne, Victoria, Austrália, VIC 3004
        • Recrutamento
        • The Alfred Hospital
      • Brasília, Brasil, 70390140
        • Recrutamento
        • Instituto Dor de Pesquisa E Ensino Distrito Federal
      • Porto Alegre, Brasil, 90110-270
        • Recrutamento
        • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
      • Salvador, Brasil, 41950-640
        • Recrutamento
        • Ensino E Terapia de Inovacao Clinica Amo Etica
      • São Paulo, Brasil, 05652-900
        • Recrutamento
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brasil, 01401-004
        • Recrutamento
        • Instituto Dor de Pesquisa E Ensino Sao Paulo
    • British Columbia
      • Victoria, British Columbia, Canadá, V8R 6V5
        • Recrutamento
        • Bc Cancer Victoria
    • Ontario
      • Hamilton, Ontario, Canadá, L8V 5C2
        • Recrutamento
        • Juravinski Cancer Centre
    • Quebec
      • Montreal, Quebec, Canadá, QC H3t 1E2
        • Recrutamento
        • Jewish General Hospital
      • Montreal, Quebec, Canadá, H4J 1C5
        • Recrutamento
        • Ciusss Nim Hscm
      • Québec, Quebec, Canadá, G1J 1Z4
        • Recrutamento
        • Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)
      • Sherbrooke, Quebec, Canadá, J1H 5N4
        • Recrutamento
        • Ciusss de Lestrie Chus
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100730
        • Recrutamento
        • Peking Union Medical College Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 630014
        • Recrutamento
        • The First Affiliated Hospital of Chongqing Medical University
    • Fujian
      • Fuzhou, Fujian, China, 350005
        • Recrutamento
        • The First Affiliated Hospital of Fujian Medical University
    • Guangdong
      • Guangzhou, Guangdong, China, 510555
        • Recrutamento
        • Sun Yat Sen University Cancer Center Huangpu Branch
      • Guangzhou, Guangdong, China, 510000
        • Ativo, não recrutando
        • Zhujiang Hospital of Southern Medical University
    • Guangxi
      • Nanning, Guangxi, China, 530021
        • Recrutamento
        • The First Affiliated Hospital of Guangxi Medical University
    • Guizhou
      • Guiyang, Guizhou, China, 550002
        • Recrutamento
        • Guizhou Provincial Peoples Hospital
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150000
        • Recrutamento
        • Harbin Medical University Cancer Hospital
    • Henan
      • Zhengzhou, Henan, China, 450000
        • Recrutamento
        • Henan Cancer Hospital
    • Hunan
      • Changsha, Hunan, China, 410011
        • Recrutamento
        • The Second Xiangya Hospital of Central South University
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Recrutamento
        • Jiangsu Province Hospital
      • Nantong, Jiangsu, China, 201203
        • Recrutamento
        • Affiliated Hospital of Nantong University
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Recrutamento
        • The Second Affiliated Hospital of Nanchang University
    • Shaanxi
      • Xi'an, Shaanxi, China, 710004
        • Recrutamento
        • The Second Affiliated Hospital of Xian Jiaotong University
    • Shandong
      • Jinan, Shandong, China, 250000
        • Recrutamento
        • Shandong Provincial Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200025
        • Recrutamento
        • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
    • Sichuan
      • Chengdu, Sichuan, China, 610071
        • Recrutamento
        • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300020
        • Recrutamento
        • Institute of Hematology and Hospital of Blood Disease
    • Yunnan
      • Kunming, Yunnan, China, 650032
        • Recrutamento
        • First Affiliated Hospital of Kunming Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310002
        • Recrutamento
        • The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan
    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, Coréia do Sul, 13620
        • Recrutamento
        • Seoul National University Bundang Hospital
    • Seoul Teugbyeolsi
      • SeochoGu, Seoul Teugbyeolsi, Coréia do Sul, 06591
        • Recrutamento
        • The Catholic University of Korea, Seoul St Marys Hospital
      • SeodaemunGu, Seoul Teugbyeolsi, Coréia do Sul, 03722
        • Recrutamento
        • Severance Hospital Yonsei University Health System
      • Seoul, Seoul Teugbyeolsi, Coréia do Sul, 03080
        • Recrutamento
        • Seoul National University Hospital
      • SongpaGu, Seoul Teugbyeolsi, Coréia do Sul, 05505
        • Recrutamento
        • Asan Medical Center
      • Granada, Espanha, 18014
        • Recrutamento
        • Hospital Universitario Virgen de Las Nieves
      • Madrid, Espanha, 28041
        • Recrutamento
        • Hospital Universitario 12 de Octubre
      • Majadahonda, Espanha, 28222
        • Recrutamento
        • Hospital Universitario Puerta de Hierro Majadahonda
      • Murcia, Espanha, 30120
        • Recrutamento
        • Hospital Clinico Universitario Virgen de La Arrixaca
    • California
      • Duarte, California, Estados Unidos, 91010-3012
        • Recrutamento
        • City of Hope National Medical Center
      • Orange, California, Estados Unidos, 92868-3201
        • Recrutamento
        • Chao Family Comprehensive Cancer Center
      • Palo Alto, California, Estados Unidos, 94304-2205
        • Recrutamento
        • Stanford Cancer Institute
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80012-5405
        • Recrutamento
        • Rocky Mountain Cancer Centers (Williams) Usor
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32224-1865
        • Recrutamento
        • Mayo Clinic Jacksonville
      • Miami, Florida, Estados Unidos, 33140
        • Recrutamento
        • Mount Sinai Medical Center Braman Comprehensive Cancer Center
      • Tampa, Florida, Estados Unidos, 33612-9496
        • Recrutamento
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Recrutamento
        • Northwestern University
      • Zion, Illinois, Estados Unidos, 60099-2676
        • Recrutamento
        • Midwestern Regional Medical Center
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70121-2429
        • Recrutamento
        • Ochsner Clinic Foundation
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215-5418
        • Recrutamento
        • Dana Farber Cancer Institute
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905-0001
        • Recrutamento
        • Mayo Clinic Rochester
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68198
        • Recrutamento
        • University of Nebraska Medical Center
    • New York
      • New York, New York, Estados Unidos, 10032
        • Recrutamento
        • Columbia University Medical Center
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204-2990
        • Recrutamento
        • Atrium Health Levine Cancer Institute (Lci)
      • Durham, North Carolina, Estados Unidos, 27705-3976
        • Recrutamento
        • Duke University Medical Center
    • Oregon
      • Eugene, Oregon, Estados Unidos, 97401
        • Recrutamento
        • Oncology Associates of Oregon Willamette Valley Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232-1309
        • Recrutamento
        • Upmc Hillman Cancer Center(Univ of Pittsburgh)
    • Texas
      • Tyler, Texas, Estados Unidos, 75702-7522
        • Recrutamento
        • Texas Oncology Tyler
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112-5550
        • Recrutamento
        • Huntsman Cancer Institute
    • Washington
      • Seattle, Washington, Estados Unidos, 98109-4433
        • Recrutamento
        • Fred Hutchinson Cancer Research Center
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226-3522
        • Recrutamento
        • Medical College of Wisconsin
      • Bordeaux, França, 33076
        • Recrutamento
        • Centre de Lutte Contre Le Cancer Institut Bergonie
      • ClermontFerrand, França, 63100
        • Recrutamento
        • Chu Clermont Ferrand Therapie Cellulaire and Hematolo
      • Le Mans, França, 72037
        • Recrutamento
        • Centre Hospitalier Le Mans
      • Lille, França, 59000
        • Recrutamento
        • Hopital Claude Huriez Chu Lille
      • Lyon, França, 69373
        • Recrutamento
        • Centre Leon Berard
      • Montpellier, França, 34090
        • Recrutamento
        • Chu Montpellier Hopital Saint Eloi
      • Toulouse, França, 31100
        • Recrutamento
        • Iuc Toulouse Oncopole
      • Almere Stad, Holanda, 1315 RA
        • Recrutamento
        • Flevoziekenhuis
      • Dordrecht, Holanda, 3318 AT
        • Recrutamento
        • Albert Schweitzer Ziekenhuis
      • Sgravenhage, Holanda, 2545 AA
        • Recrutamento
        • Hagaziekenhuis
      • Bologna, Itália, 40138
        • Recrutamento
        • Irccs Azienda Ospedaliero Universitaria Bologna
      • Florence, Itália, 50134
        • Recrutamento
        • Aou Careggi, Servizio Sanitario Toscana
      • Milan, Itália, 20132
        • Recrutamento
        • Ospedale San Raffaele
      • Milan, Itália, 20162
        • Recrutamento
        • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
      • Padova, Itália, 35128
        • Recrutamento
        • Azienda Ospedaliera Di Padova
      • Roma, Itália, 00168
        • Recrutamento
        • Fondazione Policlinico Universitario Agostino Gemelli
      • Auckland, Nova Zelândia, 1023
        • Recrutamento
        • Auckland City Hospital
      • Auckland, Nova Zelândia, 0622
        • Recrutamento
        • North Shore Hospital
      • Christchurch, Nova Zelândia, 8011
        • Recrutamento
        • Health New Zealand Canterbury
      • Dunedin, Nova Zelândia, 9016
        • Recrutamento
        • Dunedin Hospital
      • Wellington, Nova Zelândia, 6021
        • Recrutamento
        • Wellington Regional Hospital (Ccdhb)
      • Brzozów, Polônia, 36-200
        • Recrutamento
        • Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
      • Katowice, Polônia, 40-519
        • Recrutamento
        • Pratia Onkologia Katowice
      • Krakow, Polônia, 30-727
        • Recrutamento
        • Pratia McM Krakow
      • Lublin, Polônia, 20-090
        • Recrutamento
        • Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
      • Wroclaw, Polônia, 50-367
        • Recrutamento
        • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
      • Birmingham, Reino Unido, B15 2TH
        • Recrutamento
        • Queen Elizabeth Hospital
      • Bournemouth, Reino Unido, BH7 7DW
        • Recrutamento
        • University Hospitals Dorset Royal Bournemouth Hospital
      • Leeds, Reino Unido, LS9 7TF
        • Recrutamento
        • St Jamess University Hospital
      • London, Reino Unido, SE5 9RS
        • Recrutamento
        • Kings College Hospital
      • Norwich, Reino Unido, NR4 7UY
        • Recrutamento
        • Norfolk and Norwich University Hospitals Nhs Foundation Trust
      • Bucharest, Romênia, 30171
        • Recrutamento
        • Coltea Clinical Hospital
      • Bucureti, Romênia, 022328
        • Recrutamento
        • Institutul Clinic Fundeni
      • ClujNapoca, Romênia, 400015
        • Recrutamento
        • Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca
      • Stockholm, Suécia, 171 76
        • Recrutamento
        • Karolinska Universitetssjukhuset Solna
      • Brno, Tcheca, 625 00
        • Recrutamento
        • Fakultni Nemocnice Brno
      • Hradec Králové, Tcheca, 500 03
        • Recrutamento
        • Fakultni Nemocnice Hradec Kralove
      • Olomouc, Tcheca, 77900
        • Recrutamento
        • Fakultni Nemocnice Olomouc
      • Ostrava, Tcheca, 708 00
        • Recrutamento
        • Fakultni Nemocnice Ostrava
      • PLZE, Tcheca, 323 00
        • Recrutamento
        • Fakultni Nemocnice Plzen
      • Prague, Tcheca, 10000
        • Recrutamento
        • Vseobecna Fakultni Nemocnice V Praze

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
  • Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
  • Measurable disease by Computer Tomography/Magnetic Resonance Imaging
  • Adequate bone marrow and organ function

Exclusion Criteria:

  • Previous systemic treatment for CLL
  • Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
  • Known central nervous system involvement
  • History of confirmed progressive multifocal leukoencephalopathy (PML)
  • Uncontrolled hypertension or clinically significant cardiovascular disease

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm A: Sonrotoclax plus Zanubrutinib

Participants will receive sonrotoclax and zanubrutinib for a fixed duration followed by observation.

Administered orally.

Outros nomes:
  • BGB-11417

Administered orally.

Outros nomes:
  • Brukinsa
  • BGB-3111
Comparador Ativo: Arm B: Venetoclax plus Acalabrutinib

Participants will receive venetoclax and acalabrutinib for a fixed duration followed by observation.

Administered orally.

Outros nomes:
  • Cálculo

Administered orally.

Outros nomes:
  • Venclexta
  • Venclyxto

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC)
Prazo: Up to approximately 70 months

PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first.

Up to approximately 70 months
Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4)
Prazo: Up to approximately 16 months

Rate of uMRD4 is defined as the percentage of participants that achieved uMRD4 measured in both peripheral blood (PB) and bone marrow aspirate (BMA) at the post-treatment follow-up visit (PTFU1) based on next generation sequencing (NGS).

Up to approximately 16 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
PFS in High-Risk Participants
Prazo: Up to approximately 70 months

PFS is defined as the time from the date of randomization to the date of disease progression as determined by IRC or death due to any cause, whichever occurs first.

Up to approximately 70 months
Overall Survival (OS)
Prazo: Up to approximately 70 months

OS is defined as the time from the date of randomization to the date of death due to any cause.

Up to approximately 70 months
Overall Response Rate (ORR) as Determined by IRC
Prazo: Up to approximately 70 months

ORR is defined as the percentage of participants with a complete response (CR), complete response with incomplete hematopoietic recovery (CRi), nodal partial response (nPR), or partial response (PR), before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by IRC.

Up to approximately 70 months
Rate of Undetectable Minimal Residual Disease at < 10^-5 sensitivity (uMRD5)
Prazo: Up to approximately 16 months

Rate of uMRD5 is defined as the percentage of participants who achieved uMRD5 measured in both PB and BMA at the PTFU1 Visit based on NGS, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier).

Up to approximately 16 months
Number of Participants with Adverse Events
Prazo: Up to approximately 70 months

Number of participants with treatment-emergent adverse events (TEAEs), adverse events of clinical interest, and serious adverse events (SAEs), including laboratory values, vital signs, and physical examination findings.

Up to approximately 70 months
PFS Determined by Investigator Assessment
Prazo: Up to approximately 70 months

PFS is defined as the time from the date of randomization to the date of disease progression as determined by investigator or death due to any cause, whichever occurs first.

Up to approximately 70 months
Complete Response Rate (CRR) by IRC and Investigator Assessment
Prazo: Up to approximately 70 months

CRR is defined as the percentage of participants with a CR or CRi before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier).

Up to approximately 70 months
ORR Determined by Investigator Assessment
Prazo: Up to approximately 70 months

ORR is defined as the percentage of participants with a complete response or partial response, before disease progression, death, or the start of new anti-CLL treatment (whichever is earlier), as assessed by investigator.

Up to approximately 70 months
Duration of Response (DOR)
Prazo: Up to approximately 70 months

Duration of response (determined by both IRC and investigator assessment) is defined as the time from the first qualifying response (CR, CRi, nPR, or PR) until CLL progression or death. DOR analysis will only include responders.

Up to approximately 70 months
Time to Next Treatment (TTNT)
Prazo: Up to approximately 70 months

TTNT is defined as the time from randomization to the start of the next treatment for CLL.

Up to approximately 70 months
Change from Baseline in Score on European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)-409 Questionnaire
Prazo: At baseline and up to approximately 70 months

Patient-reported symptoms of global health status (GHS), role functioning, and physical functioning, symptom burden and physical condition/fatigue will be measured using the European Organization for Research and Treatment of Cancer quality of life questionnaire EORTC IL-409 (an itemized version of [EORTC] quality of life questionnaire core 30 [QLQ-C30] and its CLL module CLL17). The EORTC-IL-409 consists of 17 questions answered on a 4-point scale where 1 = Not at all (best) to 4 = Very Much (worst) and 2 global health questions answered on a 7-point scale where 1 = Very poor (worst) to 7 = Excellent (best). Higher scores in GHS and functional scales and lower scores in symptom scales indicate better quality of life.

At baseline and up to approximately 70 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Study Director, BeOne Medicines

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

22 de janeiro de 2026

Conclusão Primária (Estimado)

1 de fevereiro de 2031

Conclusão do estudo (Estimado)

1 de novembro de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

2 de dezembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de dezembro de 2025

Primeira postagem (Real)

11 de dezembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

28 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • BGB-11417-304
  • 2025-524366-21-00 (Ctis)
  • 2025 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Prazo de Compartilhamento de IPD

See plan description

Critérios de acesso de compartilhamento IPD

See plan description

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .